AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23454666 — intervention group
Group type: COMPARATOR
Intervention: printed educational material (PEM)
Number of subjects: 750
Study 22051486 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Paste Plus
Number of subjects: 60
Study 22051486 — intervention group
Group type: COMPARATOR
Intervention: Placebo paste
Number of subjects: 60
Study 19691545 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive‐behavior therapy (CBT)
Number of subjects: 24
Study 19691545 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group (waitlist control)
Number of subjects: 24
Study 15190831 — intervention group
Group type: EXPERIMENTAL
Intervention: Viagra combined with behavior therapy
Number of subjects: 60
Study 15190831 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy alone (control group)
Number of subjects: 60
Study 10365361 — intervention group
Group type: EXPERIMENTAL
Intervention: Mania-ADHD
Number of subjects: 151
Study 10365361 — intervention group
Group type: COMPARATOR
Intervention: ADHD only
Number of subjects: 151
Study 7741071 — intervention group
Group type: EXPERIMENTAL
Intervention: DES (500 mg daily injection) for 7 days before LH-RH analogue (3.6 mg of Zoladex depot)
Number of subjects: 16
Study 7741071 — intervention group
Group type: EXPERIMENTAL
Intervention: DES (500 mg injection) for 7 days prior to LH-RH analogue, plus additional DES injection for 7 days
Number of subjects: 16
Study 7741071 — intervention group
Group type: EXPERIMENTAL
Intervention: DES (500 mg injection) for 7 days simultaneously with LH-RH analogue
Number of subjects: 16
Study 7741071 — intervention group
Group type: EXPERIMENTAL
Intervention: DES (500 mg injection) for 7 days prior to LH-RH analogue, plus additional DES injection for 3 days
Number of subjects: 16
Study 1970298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg daily (increased to 20 mg if necessary)
Number of subjects: 12
Study 1970298 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg daily (increased to 100 mg if necessary)
Number of subjects: 12
Study 7027819 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol (Bronchospasmin)
Number of subjects: 90
Study 7027819 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutalin (Bricanyl)
Number of subjects: 90
Study 7027819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (Berotec)
Number of subjects: 90
Study 31775686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-Pyrimethamine (IPTp-SP) administered during pregnancy
Number of subjects: 556
Study 31775686 — intervention group
Group type: EXPERIMENTAL
Intervention: Having secondary or higher education
Number of subjects: 556
Study 31775686 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending ≥4 ANC visits
Number of subjects: 556
Study 31775686 — intervention group
Group type: EXPERIMENTAL
Intervention: Having first antenatal booking at < 17 weeks
Number of subjects: 556
Study 31775686 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate knowledge on IPTp-SP
Number of subjects: 556
Study 31775686 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care workers' knowledge about IPTp-SP
Number of subjects: 556
Study 31775686 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of SP in health facilities
Number of subjects: 556
Study 31775686 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Observed Therapy (DOT) for SP administration
Number of subjects: 556
Study 28267474 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 75 mg daily
Number of subjects: 240
Study 28267474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 27852711 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication treatment (MT) plus percutaneous transluminal angioplasty and stenting (PTAS)
Number of subjects: 0
Study 27852711 — intervention group
Group type: COMPARATOR
Intervention: Medication treatment (MT) alone
Number of subjects: 0
Study 27852711 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication treatment (MT) plus PTAS
Number of subjects: 0
Study 25118680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement-free prostheses
Number of subjects: 105
Study 25118680 — intervention group
Group type: COMPARATOR
Intervention: Cemented shaft implants
Number of subjects: 105
Study 21726302 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 801
Study 18570696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sourdough bread
Number of subjects: 10
Study 18570696 — intervention group
Group type: COMPARATOR
Intervention: Whole wheat breads
Number of subjects: 10
Study 17445639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day
Number of subjects: 120
Study 17445639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day plus Tolterodine 2 mg (twice a day)
Number of subjects: 120
Study 17445639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg (twice a day)
Number of subjects: 120
Study 17445639 — intervention group
Group type: COMPARATOR
Intervention: No medical treatment (control group)
Number of subjects: 120
Study 15649317 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1996
Study 15649317 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 1996
Study 12202454 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 12202454 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 12202454 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 12202454 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 12202454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0
Study 9825504 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute viral hepatitis B patients with severe form
Number of subjects: 0
Study 9825504 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute viral hepatitis B patients with moderate form
Number of subjects: 0
Study 9825504 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute viral hepatitis B patients (general)
Number of subjects: 0
Study 8085623 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 2 mg/kg
Number of subjects: 30
Study 8085623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2782514 — intervention group
Group type: EXPERIMENTAL
Intervention: 5th grade reading level booklet
Number of subjects: 129
Study 2782514 — intervention group
Group type: EXPERIMENTAL
Intervention: 10th grade reading level booklet
Number of subjects: 129
Study 2782514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smoking booklet)
Number of subjects: 129
Study 31303116 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherers
Number of subjects: 18
Study 31303116 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adherers
Number of subjects: 18
Study 31303116 — intervention group
Group type: COMPARATOR
Intervention: Reminder interventions
Number of subjects: 18
Study 28640984 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery for colorectal cancer
Number of subjects: 5680
Study 28640984 — intervention group
Group type: COMPARATOR
Intervention: Traditional open surgery for colorectal cancer
Number of subjects: 5680
Study 26475583 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 32
Study 26475583 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exercise
Number of subjects: 32
Study 23356392 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 µg fluticasone dipropionate and 25 µg salmeterol, two actuations twice daily, by either separate or combination ICS/LABA inhalers
Number of subjects: 111
Study 23356392 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report
Number of subjects: 111
Study 23356392 — intervention group
Group type: EXPERIMENTAL
Intervention: Underuse of inhalers
Number of subjects: 111
Study 23356392 — intervention group
Group type: EXPERIMENTAL
Intervention: Overuse of inhalers
Number of subjects: 111
Study 21329753 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depressive disorder
Number of subjects: 104
Study 21329753 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medications
Number of subjects: 104
Study 22009824 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-coated lumbar interbody fusion system
Number of subjects: 94
Study 17923575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saver
Number of subjects: 226
Study 17923575 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 226
Study 14683739 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu vaccination
Number of subjects: 296
Study 14683739 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 296
Study 12421196 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 25
Study 12421196 — intervention group
Group type: EXPERIMENTAL
Intervention: Laudanosine
Number of subjects: 25
Study 12421196 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 25
Study 9803088 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education intervention
Number of subjects: 0
Study 9803088 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos and informational cartoons as media for intervention
Number of subjects: 0
Study 8128175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (5 mg three times daily)
Number of subjects: 60
Study 8128175 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg three times daily)
Number of subjects: 60
Study 2491470 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 6
Study 2491470 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 6
Study 2491470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 163937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with 0.3 percent 'Neutralrot' eye drops and radiation with daylight lamp HPR 125 W.
Number of subjects: 0
Study 163937 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye drops of corticosteroid content.
Number of subjects: 0
Study 163937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular inoculation with Interferonogen.
Number of subjects: 0
Study 163937 — intervention group
Group type: COMPARATOR
Intervention: 'Okuzell-Coldan' eye drops as placebo.
Number of subjects: 0
Study 31120504 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention supported by a smartphone application
Number of subjects: 112
Study 31565969 — intervention group
Group type: EXPERIMENTAL
Intervention: NCAA Fact Sheet for Coaches (intervention condition)
Number of subjects: 779
Study 31565969 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 779
Study 28526538 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (3.6 mg/kg intravenously every 21 days)
Number of subjects: 602
Study 28526538 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice
Number of subjects: 602
Study 28526538 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Number of subjects: 602
Study 26087637 — intervention group
Group type: COMPARATOR
Intervention: diclofenac sodium 100 mg/day
Number of subjects: 86
Study 26087637 — intervention group
Group type: EXPERIMENTAL
Intervention: Alflutop injection 1 ml per day for 20 days, then 2 ml intraarticular twice weekly in the following month
Number of subjects: 86
Study 26087637 — intervention group
Group type: EXPERIMENTAL
Intervention: diacerein (diaflex, 'Rompharm Company') 50 mg twice daily for 3 months
Number of subjects: 86
Study 23921483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium-enriched yeast (100 μg daily for 2 weeks)
Number of subjects: 11
Study 23921483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium-enriched yeast (200 μg daily for 6 weeks)
Number of subjects: 11
Study 23921483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium-enriched yeast (100 μg and 200 μg daily)
Number of subjects: 11
Study 23921483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium-enriched yeast (after 8 weeks washout)
Number of subjects: 11
Study 23921483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium-enriched yeast
Number of subjects: 11
Study 21519733 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine group (50 g L-glutamine, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Number of subjects: 56
Study 21519733 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate group (12.5% maltodextrine, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Number of subjects: 56
Study 21519733 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (water, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Number of subjects: 56
Study 21519733 — intervention group
Group type: COMPARATOR
Intervention: Fasted group (conventional preoperative fasting of 8 hours)
Number of subjects: 56
Study 18816360 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped self-modeling and positive feedback about father-infant interaction provided by specially trained nurses
Number of subjects: 81
Study 18816360 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped self-modeling and positive feedback about father-infant interaction
Number of subjects: 81
Study 17415601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) imaging
Number of subjects: 20
Study 17415601 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 20
Study 15234503 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Kirschner wires
Number of subjects: 0
Study 15234503 — intervention group
Group type: COMPARATOR
Intervention: Buried Kirschner wires
Number of subjects: 0
Study 11724442 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to IFN-gamma
Number of subjects: 45
Study 11724442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11724442 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to TNF-alpha
Number of subjects: 45
Study 9404216 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans performed at 40 mAs
Number of subjects: 0
Study 9404216 — intervention group
Group type: COMPARATOR
Intervention: CT scans performed at 60 mAs
Number of subjects: 0
Study 8492200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-codeine (400 mg ibuprofen + 60 mg codeine)
Number of subjects: 60
Study 8492200 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 60
Study 3819254 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAPEDOWN program
Number of subjects: 66
Study 30508936 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 200
Study 30508936 — intervention group
Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 200
Study 27706551 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum Power Load (OPL)
Number of subjects: 23
Study 27706551 — intervention group
Group type: COMPARATOR
Intervention: Traditional Strength-Power Periodization (TSP)
Number of subjects: 23
Study 25355671 — intervention group
Group type: EXPERIMENTAL
Intervention: Common project-based European identity prime
Number of subjects: 206
Study 25355671 — intervention group
Group type: COMPARATOR
Intervention: Common heritage-based European identity prime
Number of subjects: 206
Study 24329692 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS (active)
Number of subjects: 59
Study 24329692 — intervention group
Group type: COMPARATOR
Intervention: 10 Hz rTMS (active)
Number of subjects: 59
Study 24329692 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 59
Study 20597358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received one session of psycho-education about self-complexity and kept daily records for one week)
Number of subjects: 40
Study 20597358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 20597358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 40
Study 18822909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine plus citicoline (group A)
Number of subjects: 300
Study 18822909 — intervention group
Group type: COMPARATOR
Intervention: Ligustrazine alone (group B)
Number of subjects: 300
Study 18822909 — intervention group
Group type: COMPARATOR
Intervention: Citicoline alone (group C)
Number of subjects: 300
Study 17121048 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in Siguan points combined with intravenous midazolam injection
Number of subjects: 60
Study 17121048 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam injection
Number of subjects: 60
Study 12541156 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb (up to 1000 ml of a 10% diaspirin cross‐linked hemoglobin solution)
Number of subjects: 121
Study 12541156 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 121
Study 12541156 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb
Number of subjects: 121
Study 10710206 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (3 MU subcutaneously every 24 hr)
Number of subjects: 256
Study 10710206 — intervention group
Group type: COMPARATOR
Intervention: ZDV and ddC (control group)
Number of subjects: 256
Study 9347091 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. human (h) CRF
Number of subjects: 11
Study 9347091 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted stress test
Number of subjects: 11
Study 9347091 — intervention group
Group type: COMPARATOR
Intervention: Block I (baseline)
Number of subjects: 11
Study 9347091 — intervention group
Group type: COMPARATOR
Intervention: Block II (after 12 weeks of abstinence)
Number of subjects: 11
Study 8445202 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (initial bolus of 30 mg/kg followed by infusion of 5.4 mg/kg/h over 23 hours)
Number of subjects: 0
Study 8445202 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0
Study 8445202 — intervention group
Group type: COMPARATOR
Intervention: Control (naloxone or placebo)
Number of subjects: 0
Study 3528240 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics plus elastic support bandages
Number of subjects: 47
Study 3528240 — intervention group
Group type: COMPARATOR
Intervention: Elastic support bandages only
Number of subjects: 47
Study 29550766 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg with loading dose (LD)
Number of subjects: 996
Study 29550766 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg with loading dose (LD)
Number of subjects: 996
Study 29550766 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg without loading dose (LD)
Number of subjects: 996
Study 29550766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 996
Study 27218418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonswallow procedure for nasogastric tube insertion
Number of subjects: 80
Study 27218418 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard nasogastric tube insertion)
Number of subjects: 80
Study 24504006 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice-daily for 12 months
Number of subjects: 148
Study 24504006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 22146609 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 32
Study 22146609 — intervention group
Group type: COMPARATOR
Intervention: Conventional walking treatment (CWT)
Number of subjects: 32
Study 20346183 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory return-to-work program
Number of subjects: 0
Study 20346183 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18652967 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization exercise in addition to standard care
Number of subjects: 60
Study 18652967 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 16243131 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 J/cm2
Number of subjects: 27
Study 16243131 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 J/cm2
Number of subjects: 27
Study 16243131 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 J/cm2
Number of subjects: 27
Study 16243131 — intervention group
Group type: COMPARATOR
Intervention: All light doses (70, 100, 140 J/cm2)
Number of subjects: 27
Study 12105366 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced cerebrovascular reactivity (rCVR) to acetazolamide
Number of subjects: 70
Study 12105366 — intervention group
Group type: COMPARATOR
Intervention: Normal cerebrovascular reactivity (rCVR) to acetazolamide
Number of subjects: 70
Study 12105366 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 70
Study 12105366 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA or MCA occlusion with reduced rCVR
Number of subjects: 70
Study 12105366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower rCVR and resting regional cerebral blood flow values
Number of subjects: 70
Study 10485080 — intervention group
Group type: EXPERIMENTAL
Intervention: CAI with a standardized high fat meal
Number of subjects: 12
Study 10485080 — intervention group
Group type: COMPARATOR
Intervention: CAI fasting
Number of subjects: 12
Study 7612530 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntometrine
Number of subjects: 1000
Study 3058374 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (50 micrograms subcutaneously)
Number of subjects: 5
Study 3058374 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 5
Study 28922786 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)
Number of subjects: 6815
Study 28922786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 6815
Study 28922786 — intervention group
Group type: COMPARATOR
Intervention: Observation (No IFN)
Number of subjects: 6815
Study 28578654 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week progressive resistance training (PRT) program
Number of subjects: 72